dopamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	947	51-61-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dopamine oxytyramine dopamin dophamine hydroxytyramin dopamine hydrochloride dopamine HCl	One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Molecular weight: 153.18 Formula: C8H11NO2 CLOGP: 0.17 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 66.48 ALOGS: -1.31 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dopamine
oxytyramine
dopamin
dophamine
hydroxytyramin
dopamine hydrochloride
dopamine HCl

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.

Molecular weight: 153.18
Formula: C8H11NO2
CLOGP: 0.17
LIPINSKI: 0
HAC: 3
HDO: 3
TPSA: 66.48
ALOGS: -1.31
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	470 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.74 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	65.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	18.96 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1974	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	101.53	25.37	56	3979	56696	63428291
Renal ischaemia	73.89	25.37	15	4020	618	63484369
Cardiac arrest	69.68	25.37	53	3982	92492	63392495
Drug ineffective	65.51	25.37	178	3857	1044587	62440400
PCO2 increased	63.85	25.37	15	4020	1224	63483763
Hypotension	61.76	25.37	81	3954	272523	63212464
Blood bicarbonate decreased	59.90	25.37	17	4018	2924	63482063
Left ventricle outflow tract obstruction	59.12	25.37	11	4024	285	63484702
PO2 increased	57.92	25.37	13	4022	866	63484121
Diabetes insipidus	57.21	25.37	16	4019	2609	63482378
Cardiogenic shock	56.53	25.37	26	4009	17906	63467081
Blood pH decreased	52.89	25.37	15	4020	2572	63482415
Oxygen saturation abnormal	52.53	25.37	16	4019	3513	63481474
Status epilepticus	50.89	25.37	23	4012	15210	63469777
Shock	47.04	25.37	25	4010	23438	63461549
Renal impairment	46.28	25.37	41	3994	88314	63396673
Foetal death	44.52	25.37	19	4016	10961	63474026
Bradycardia	40.39	25.37	35	4000	73192	63411795
Electroencephalogram abnormal	39.52	25.37	13	4022	3659	63481328
Ventricular tachycardia	39.24	25.37	21	4014	19958	63465029
Enzyme induction	37.98	25.37	6	4029	56	63484931
Clonus	36.55	25.37	13	4022	4623	63480364
Cardiopulmonary failure	35.73	25.37	12	4023	3600	63481387
Blood magnesium decreased	35.02	25.37	17	4018	13181	63471806
Metabolic acidosis	34.28	25.37	26	4009	45043	63439944
Seizure	34.02	25.37	42	3993	132592	63352395
Renal injury	33.91	25.37	15	4020	9424	63475563
Pulmonary oedema	33.89	25.37	28	4007	54845	63430142
Left ventricular dysfunction	33.50	25.37	16	4019	11972	63473015
Electrocardiogram QRS complex prolonged	33.41	25.37	13	4022	5925	63479062
Disseminated intravascular coagulation	31.83	25.37	18	4017	19033	63465954
Blood pressure decreased	31.71	25.37	29	4006	64993	63419994
Renal failure	31.37	25.37	38	3997	117614	63367373
Cardiac assistance device user	31.25	25.37	5	4030	51	63484936
Newborn persistent pulmonary hypertension	29.99	25.37	6	4029	229	63484758
Platelet count decreased	28.53	25.37	36	3999	116086	63368901
Septic shock	27.32	25.37	27	4008	66602	63418385
Myocardial ischaemia	26.61	25.37	14	4021	12845	63472142
Systolic anterior motion of mitral valve	26.47	25.37	4	4031	27	63484960
Respiratory failure	25.69	25.37	32	4003	101826	63383161

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	68.50	21.90	156	3834	456595	34496346
Multiple organ dysfunction syndrome	58.92	21.90	57	3933	76509	34876432
Disseminated intravascular coagulation	49.76	21.90	31	3959	21785	34931156
Hypotension	43.76	21.90	85	3905	221564	34731377
Shock	39.72	21.90	28	3962	24151	34928790
Torsade de pointes	38.40	21.90	18	3972	7191	34945750
Blood urea increased	38.30	21.90	30	3960	30334	34922607
Ventricular fibrillation	34.08	21.90	25	3965	22929	34930012
Cardiac arrest	32.50	21.90	47	3943	96112	34856829
Acute kidney injury	31.66	21.90	91	3899	304897	34648044
Metabolic acidosis	30.72	21.90	31	3959	43649	34909292
Oliguria	24.55	21.90	14	3976	8366	34944575
Renal failure	24.38	21.90	49	3941	130508	34822433
Neutrophil count increased	23.93	21.90	18	3972	17128	34935813
Lymphocyte count decreased	23.56	21.90	20	3970	22602	34930339
Acidosis	23.56	21.90	15	3975	10930	34942011
Respiratory failure	23.01	21.90	43	3947	108529	34844412
Dry gangrene	22.77	21.90	6	3984	433	34952508
Cardiogenic shock	22.68	21.90	21	3969	26597	34926344

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	114.96	21.18	92	7193	120154	79616949
Drug ineffective	106.54	21.18	274	7011	1080639	78656464
Hypotension	89.82	21.18	151	7134	440166	79296937
Cardiac arrest	88.45	21.18	93	7192	172003	79565100
Shock	78.16	21.18	49	7236	43499	79693604
Disseminated intravascular coagulation	76.32	21.18	45	7240	35797	79701306
Cardiogenic shock	67.37	21.18	44	7241	41870	79695233
Renal ischaemia	59.39	21.18	15	7270	1147	79735956
Blood urea increased	59.03	21.18	43	7242	48747	79688356
PCO2 increased	57.08	21.18	16	7269	1824	79735279
Ventricular fibrillation	52.49	21.18	34	7251	31892	79705211
Left ventricle outflow tract obstruction	51.47	21.18	11	7274	402	79736701
Metabolic acidosis	50.37	21.18	49	7236	82480	79654623
Diabetes insipidus	47.80	21.18	18	7267	5219	79731884
Septic shock	47.02	21.18	57	7228	122744	79614359
Ventricular tachycardia	46.33	21.18	35	7250	41900	79695203
Renal impairment	45.99	21.18	64	7221	157719	79579384
Blood pH decreased	45.95	21.18	17	7268	4694	79732409
PO2 increased	45.60	21.18	13	7272	1575	79735528
Respiratory failure	44.90	21.18	68	7217	180843	79556260
Blood bicarbonate decreased	44.34	21.18	17	7268	5174	79731929
Foetal death	43.56	21.18	19	7266	8025	79729078
Acute kidney injury	42.97	21.18	124	7161	519280	79217823
Oxygen saturation abnormal	42.73	21.18	16	7269	4566	79732537
Bradycardia	41.02	21.18	56	7229	135501	79601602
Pulmonary oedema	38.82	21.18	44	7241	88210	79648893
Renal failure	38.26	21.18	67	7218	200901	79536202
Blood pressure decreased	37.79	21.18	46	7239	99420	79637683
Fatigue	34.87	21.18	21	7264	929706	78807397
Status epilepticus	34.73	21.18	24	7261	25017	79712086
Platelet count decreased	33.35	21.18	62	7223	194602	79542501
Torsade de pointes	32.80	21.18	21	7264	19291	79717812
Enzyme induction	31.79	21.18	6	7279	115	79736988
Arthralgia	31.31	21.18	7	7278	571796	79165307
Left ventricular dysfunction	30.30	21.18	20	7265	19341	79717762
Electroencephalogram abnormal	29.96	21.18	13	7272	5421	79731682
Acidosis	29.93	21.18	20	7265	19742	79717361
Neutrophil count increased	29.11	21.18	23	7262	29373	79707730
Cardiac failure	28.64	21.18	51	7234	154791	79582312
Blood magnesium decreased	28.15	21.18	18	7267	16494	79720609
Hepatic function abnormal	28.06	21.18	34	7251	73073	79664030
Sepsis	27.92	21.18	70	7215	269358	79467745
Hypernatraemia	27.78	21.18	17	7268	14434	79722669
Seizure	27.29	21.18	56	7229	188778	79548325
Clonus	27.09	21.18	13	7272	6827	79730276
Cardiac assistance device user	26.85	21.18	5	7280	89	79737014
Incision site pain	26.82	21.18	10	7275	2820	79734283
Drug ineffective for unapproved indication	26.80	21.18	28	7257	51210	79685893
Toxic epidermal necrolysis	26.30	21.18	26	7259	44555	79692548
Circulatory collapse	24.16	21.18	23	7262	37645	79699458
Electrocardiogram QRS complex prolonged	24.09	21.18	14	7271	10819	79726284
Systolic dysfunction	23.97	21.18	10	7275	3785	79733318
Lymphocyte count decreased	23.24	21.18	25	7260	47264	79689839
Myocardial ischaemia	23.21	21.18	19	7266	25500	79711603
Hepatic failure	22.73	21.18	28	7257	61184	79675919
Haemodynamic instability	22.57	21.18	16	7269	17366	79719737
Systolic anterior motion of mitral valve	22.45	21.18	4	7281	55	79737048
Intentional overdose	22.34	21.18	37	7248	105923	79631180
Urine output decreased	22.05	21.18	16	7269	18006	79719097
N-terminal prohormone brain natriuretic peptide	21.59	21.18	4	7281	69	79737034
Sinus bradycardia	21.31	21.18	18	7267	25229	79711874
Cardiopulmonary failure	21.24	21.18	11	7274	6790	79730313

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA04	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA CS	M0003647	Catecholamines
FDA EPC	N0000175570	Catecholamine
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
CHEBI has role	CHEBI:48560	dopaminergic agents
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Low cardiac output syndrome	indication	44088000
Low blood pressure	indication	45007003
Decompensated cardiac failure	indication	195111005
Sinus bradycardia	off-label use	49710005
Acute nephropathy	off-label use	58574008
Tachyarrhythmia	contraindication	6285003
Hypovolemia	contraindication	28560003
Ventricular arrhythmia	contraindication	44103008
Acidosis	contraindication	51387008
Pheochromocytoma	contraindication	302835009
Hypoxia	contraindication	389086002
Occlusive Vascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.96	acidic
pKa2	12.98	acidic
pKa3	10.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	5	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Kd	4.19	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	9	WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		IC50	8.18	WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.08	PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	9	WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN	AGONIST	Ki	9	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.19	CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	9	WOMBAT-PK
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		Ki	6.38	WOMBAT-PK
Melatonin receptor type 1A	GPCR	P48039	MTR1A_HUMAN		Ki	5.15	CHEMBL
Melatonin receptor type 1B	GPCR	P49286	MTR1B_HUMAN		Ki	5.04	CHEMBL
Lysine-specific demethylase 4E	Enzyme	B2RXH2	KDM4E_HUMAN		IC50	5.52	CHEMBL
Dopamine beta-hydroxylase	Enzyme	P09172	DOPO_HUMAN		Km	3	WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.85	CHEMBL
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	6.28	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.35	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.70	CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_BOVIN		Ki	8.15	CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	5	CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	6.82	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	8.74	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	4.30	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.96	CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		EC50	8.62	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		IC50	5.52	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.24	CHEMBL
Dopamine receptor	GPCR		DRD2_BOVIN DRD1_BOVIN		IC50	8.43	CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT		IC50	5.27	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		Ki	4.85	CHEMBL
Adenylate cyclase	Enzyme		D4A3N4_RAT ADCY3_RAT ADCY2_RAT ADCY4_RAT ADCY8_RAT ADCY6_RAT ADCY5_RAT Q8CFM9_RAT		EC50	5.46	CHEMBL
Adenosine A2b receptor	GPCR		AA2BR_RAT		Ki	6.01	CHEMBL
M18 aspartyl aminopeptidase	Enzyme		Q8I2J3_PLAF7		IC50	5.70	CHEMBL

External reference:

ID	Source
4019733	VUID
N0000147825	NUI
D00633	KEGG_DRUG
62-31-7	SECONDARY_CAS_RN
4018656	VANDF
4019733	VANDF
C0013030	UMLSCUI
CHEBI:18243	CHEBI
LDP	PDB_CHEM_ID
CHEMBL59	ChEMBL_ID
DB00988	DRUGBANK_ID
CHEMBL1557	ChEMBL_ID
D004298	MESH_DESCRIPTOR_UI
681	PUBCHEM_CID
2417	INN_ID
940	IUPHAR_LIGAND_ID
VTD58H1Z2X	UNII
3628	RXNORM
3090	MMSL
4632	MMSL
6641	MMSL
d00216	MMSL
001787	NDDF
004721	NDDF
16257000	SNOMEDCT_US
412383006	SNOMEDCT_US
59187003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	16 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1840	INJECTION	80 mg	INTRAVENOUS	EXPORT ONLY	20 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1840	INJECTION	80 mg	INTRAVENOUS	EXPORT ONLY	20 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1880	INJECTION	800 mg	INTRAVENOUS	EXPORT ONLY	20 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1880	INJECTION	800 mg	INTRAVENOUS	EXPORT ONLY	20 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1005	INJECTION, SOLUTION	80 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1005	INJECTION, SOLUTION	80 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1007	INJECTION, SOLUTION	160 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1007	INJECTION, SOLUTION	160 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1009	INJECTION, SOLUTION	320 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1009	INJECTION, SOLUTION	320 mg	INTRAVENOUS	NDA	22 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9981	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9981	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9982	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9982	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7809	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	25 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7810	INJECTION, SOLUTION	3.20 mg	INTRAVENOUS	NDA	25 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	17 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1220	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1220	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1291	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1291	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections